

Effect of Claro on adrenal function in clinically healthy dogs

Study objectives

The purpose of this study is to determine if the application of a commonly used and widely available ear medication (Claro) for dogs, which contains a potent topical steroid, decreases natural steroid hormone production, and if so, for how long, in otherwise healthy dogs diagnosed with otitis externa.

Inclusion criteria

Dogs must be:

- 8 months - 6 years of age
- Maximum weight of 20 kg
- Bilateral otitis externa preferred

Exclusion criteria

- Use of corticosteroids (topical or systemic) within 3 months prior to entry
- Clinical suspicion of Pseudomonas otitis which would not respond to Claro administration
- A ruptured tympanic membrane as assessed on otoscopy
- Pyoderma
- Generalized pruritus
- Systemic illness

Study benefits

Involvement in the study requires 2-3 visits on days 0, 28, and 42 (if needed) within a 4-6 week period.

Benefits provided at no cost for qualifying dogs include:

- Claro otic medication
- ACTH stimulation testing
- Otoscopy and otic cytology at each visit
- Visits directly related to the study

Any additional costs will be discussed with client before they are required.



Contact information

Dr. Sarah Hoppers

saremorr@vols.utk.edu | 865-974-8387

Dr. Elizabeth Drake

elizabethdrake@tennessee.edu | 865-974-8387

Gina Galyon, LVMT (clinical trial coordinator)

ggalyon@utk.edu | 865-755-8151

IACUC PROTOCOL: 2674-0119